The Guidelines on the revised Variations Framework are applicable

The new Guidelines implement the detailed classification and procedural rules for post-authorisation changes under the revised Regulation (EC) No 1234/2008 and apply specifically to human medicinal products. Veterinary variations are addressed in separate guidance.

With the new Guidelines now in force, marketing authorisation holders (MAH) should (have) reassess(ed) internal change management processes, variation planning strategies, and documentation standards to align with the revised expectations.

Below, we provide a brief overview of selected changes and their operational business impact.

A. New Variations Guidelines: classification, documentation, and lifecycle impact

Following the amendment to the Variations Regulation¹, applicable since 1 January 2025, the European Commission adopted new guidelines on Variations (Communication C/2025/5045 - Variation Guidelines²). As of 15 January 2026, any new variations submitted, must adhere to these Guidelines as the 2013 Guidelines have been replaced.

These Variation Guidelines provide for practical improvements and more clarity regarding the classification and procedure of variations. Building on ICH Q12³ principles , classification is now explicitly risk-based, documentation expectations are higher, and lifecycle tools like Post-Approval Change Management Protocols (PACMPs), are promoted to support forward-planned changes.

The Guidelines contain expanded procedural chapters and annexes providing detailed submission requirements, documentation checklists, and assessment instructions for all variation types, aiming to reduce ambiguity in both classification and processing.

In practice, the Guidelines shift regulatory effort upstream and favour organisations with mature lifecycle planning. MAHs that embed these requirements into their process can unlock efficiencies, while reactive approaches will increasingly result in higher classifications, longer timelines, and greater operational cost.

^{1 Regulation (EU) 2024/1701 amending Regulation (EC) No 1234/2008
2 European Commission, Communication/2025/5045 (22.9.2025): Guidelines on the details of the various categories of variation, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use, and on the documentation to be submitted pursuant to those procedures
3 International Council for Harmonisation, Q12: Step 4}

The Guidelines are complemented by procedural guidance and Q&As issued by the EMA and CMDh.

B. Practical implications for MAHs

• More work upfront: classification benefits now depend on complete, submission-ready data packages at first filing.
• Earlier cross-functional involvement: Regulatory, CMC, QA, and manufacturing must align earlier to avoid escalation.
• Portfolio planning becomes critical: lifecycle strategies (including PACMPs) can materially influence timelines and workload.

C. Selected changes

The Variation Guidelines provide for guidance on a multitude of aspects, including:

1) Lower Classification if compliant with conditions and documentation

The new Guidelines explicitly reclassify a number of post-authorisation changes into lower variation categories, compared to the 2013 Guidelines, with several changes moving from Type II to Type IB or from Type IB to Type IA.

However, these downgrades are not unconditional. The same categories now contain more detailed and restrictive conditions and, in many cases, expanded documentation requirements. Access to the lower reporting category is explicitly contingent on meeting all listed conditions, with clear escalation to a higher category if any condition is not fulfilled, and with reinforced expectations for comparative data, trend analysis, and risk-based justification.

Ultimately, the new framework rewards robust upfront compliance and penalises gaps: lower categories are possible, but only with complete evidence, otherwise escalation is immediate.

2) Different reference points for Type IA vs Type IB/II

For Type IB/Type II (and grouped Type IA handled within those procedures), the submission date determines whether the old or new guideline applies.

For Type IA, the date of implementation in the MAH quality management system is the key reference point; not the submission date. This is to minimise overlap between regimes.

The CMDh guidance provides that Type IA changes implemented before 15 January 2026 should be submitted before that date (preferably via an earlier annual update, or otherwise as individual notifications). It also specifies that the first Type IA implemented from 15 January 2026 starts a new annual-update cycle (unless an annual-update exemption applies).

3) Grouping, "super-grouping," and worksharing are explicitly systematised

The revised guideline framework strengthens the practical handling of multi-change submissions by describing how to package variations efficiently. It explicitly sets out where super-grouping is possible (notably for certain Type IA notifications submitted simultaneously for multiple marketing authorisations across procedures and Member States, including scenarios where the Reference Member State (RMS) is the same). This is paired with a dedicated worksharing section covering submission and outcomes for worksharing assessments involving centrally authorised products and products authorised via other routes.

4) Combination products are now explicitly covered

For integral medicinal product-medical device combinations, the Guidelines introduce dedicated variation categories for device-related changes and align classification with EU Medical Device Regulation requirements, including Article 117 MDR where applicable.

Device modifications (for example, design, materials, or suppliers) now trigger specific documentation expectations and, where applicable, updated Notified Body input. Failure to provide this, will typically result in escalation to a higher variation category.

The practical implementation is supported by guidance from the EMA and CMDh.

5) A shift from reactive to planned change management

The framework promotes proactive lifecycle planning, encouraging the use of tools such as Post-Approval Change Management Protocols to improve predictability and reduce downstream regulatory burden.

This article was drafted with the support of Johan Jonckx.